Seronegative spondyloarthropathies: to lump or split?

Abstract

The advent of novel biological therapies for the treatment of rheumatic disease has renewed interest in the seronegative spondyloarthropathies (SpAs). International efforts are redefining disease classification and measures of disease activity, outcome, metrology, and imaging. However, opinion is divided between those who propose that the SpA group represents the same disease with variable expression (the "lumpers") and those who consider these to be separate diseases with shared clinical features (the "splitters"). This review presents the evidence for both approaches.

3 Figures and Tables

Statistics

0100200300'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

618 Citations

Semantic Scholar estimates that this publication has 618 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Nash2005SeronegativeST, title={Seronegative spondyloarthropathies: to lump or split?}, author={Peter T Nash and P. J. Mease and J{\"{u}rgen Braun and D{\'e}sir{\'e}e Mfm van der Heijde}, journal={Annals of the rheumatic diseases}, year={2005}, volume={64 Suppl 2}, pages={ii9-13} }